2024 IN REVIEW

STALLERGENES GREER

Life *beyond allergy*

CONTENTS

04 Message from the Chairman
Cyrus Jilla

06 Message from the CEO
Michele Antonelli

WHO WE ARE

10 Highlights
12 At a glance
14 Our purpose, our ambition
15 Our strategy
16 Operating review
Europe & International
North America
Western & Southern Europe
22 People & culture
26 Governance

WHAT WE DO

30 Business environment
34 Research & development
38 Technical operations

IMPACT

44 Stallergenes Greer Foundation
48 Care Beyond Allergy

PRODUCTS & PORTFOLIO

54 Products
56 Portfolio

CYRUS JILLA

I am writing to you for the first time in my capacity as Chairman of the Board of Directors of Stallergenes Greer. It is an honour for me to contribute to the platform of capabilities and innovation in allergy therapeutics that Stallergenes Greer has been building over more than 120 years. I would like to express my gratitude to Stefan Meister for his contributions to the company during his tenure as Chairman.

I am pleased to share that 2024 was another year of progress for Stallergenes Greer with strong financial performance, growth momentum across our portfolio and significant geographic expansion. Investments made over the past years in quality, industrial operations, supply chain and product development, combined with smart capital allocation and disciplined financial management are bearing fruit. It is thanks to the commitment of Stallergenes Greer colleagues across the globe, that these results were made possible. They are at the heart of our success and the promise of our future.

The coming year marks the opening of a new chapter for Stallergenes Greer with the arrival, in April 2025, of Dr Andreas Amrein as Chief Executive Officer. Andreas joins us at a time of strong opportunity for continued expansion and development within allergy therapeutics. On behalf of the Board of Directors, I extend my deepest thanks to Michele Antonelli, who has chosen to retire, for successfully leading Stallergenes Greer through a transformative period, while laying the bedrock for growth. His personal contributions and leadership have been exceptional and we wish him well for the future.

Looking forward, Stallergenes Greer is well positioned to accelerate its development. I have full confidence that the Board and the management team led by Andreas, will capitalise on our outstanding teams and other strengths of the company to capture the many opportunities to build a bright future for the benefit of our stakeholders and the more than 1.3 million patients we serve throughout the world.

CYRUS JILLA
Chairman of the Board of Directors

MICHELE ANTONELLI

I am pleased to report that 2024 was a year of success, on multiple levels, for Stallergenes Greer.

In a dynamic European market, we captured significant market share, notably in France, Germany, Italy, Spain and Poland. In Germany, we are now among the leading allergen immunotherapy players and the fastest-growing company, and in France, we leveraged changes in the allergology landscape and strengthened our positions.

We also achieved close to zero stockout in Europe and the United States thanks to the successful implementation of our make-to-stock system. As a reliable partner, we deliver our named patient products within very short, standardised lead times to effectively meet customer expectations.

Our clinical and real-world evidence studies are moving forward as planned and delivering valuable scientific data, and our teams continued to show their scientific expertise with the publication of significant data.

And, finally, our oral immunotherapy Palforzia® has been given a green light by the U.S. Food and Drug Administration and the European Medicines Agency for the extension of indication to the paediatric population.

These accomplishments have been powered by the hard work and dedication of Stallergenes Greer colleagues across the entire organisation. The passion they bring to work each day is inspiring and, for this, I am profoundly grateful.

After 10 years with Stallergenes Greer, the time has come for me to retire and hand over the reins to Dr Andreas Amrein, who will become CEO on April 1, 2025. I would like to take this opportunity to express my deepest thanks to the Board of Directors for their trust and guidance which were instrumental in transforming Stallergenes Greer.

It gives me pride to say that Stallergenes Greer is opening a new chapter with an incredibly strong foundation and teams that are determined to fulfill the Group's mission.

I am confident that under the leadership of Cyrus Jilla, Chairman of the Board, and Dr Andreas Amrein, CEO, Stallergenes Greer will soar to new heights.

MICHELE ANTONELLI
Chief Executive Officer

WHO WE ARE



2024 HIGHLIGHTS

May

Publication of the results of landmark EfficAPSI real-world study results, confirming significant benefit of Stallergenes Greer's liquid sublingual allergen immunotherapy (SLIT) on the onset and progression of allergic asthma in patients with allergic rhinitis, in The Lancet Regional Health-Europe[1].

21 publications showcased at EAACI (European Academy of Allergy and Clinical Immunology) and three scientific awards received[1].

The Stallergenes Greer Foundation announces winners of 2023 first edition of *Science Awards for Allergy*.

1. https://doi.org/10.1016/j.lanepe.2024.100915

July

Albey®, bee (Apis mellifera) and wasp (Vespula spp.) venom, is available in France.

U.S. Food and Drug Administration (FDA) approves paediatric indication extension of Palforzia® [Peanut (Arachis hypogaea) Allergen Powder-dnfp] for the treatment of toddlers (ages 1-3 years) with a confirmed diagnosis of peanut allergy in combination with a peanut-avoidant diet.

September

Launch of Palforzia® in France for the treatment, in combination with a peanut-avoidant diet, of patients aged 4-17 years with a confirmed diagnosis of peanut allergy. Palforzia® may be continued in patients aged 18 years and older.

October

Expansion of geographic footprint to the Nordic region with the opening of an affiliate in Copenhagen (Denmark).

Launch of AitGrys®, standardised 5-grass pollen sublingual immunotherapy (SLIT) tablet, in Denmark, Norway and Sweden.

Launch of AitMyte®, sublingual house dust mite immunotherapy (SLIT) tablet in Denmark, Norway and Sweden.

December

The European Commission (EC) approves the extension of indication of Palforzia® (defatted powder of Arachis hypogaea L., semen (peanut)) for the treatment of toddlers (ages 1 through 3) with a confirmed diagnosis of peanut allergy. The marketing authorisation covers all 27 European member states and the three European Economic Area states (Iceland, Liechtenstein and Norway). To date, Palforzia® is the first and only EMA and FDA approved oral immunotherapy for toddlers with a confirmed diagnosis of peanut allergy.

AT A GLANCE

Stallergenes Greer is a fully integrated global healthcare company specialising in the research, diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy (AIT) products and services. AIT is an allergy treatment designed to treat the underlying cause of the disease by rebalancing the immune system. AIT can alter the natural course of allergies and is a therapeutic class capable of modifying disease progression.

120
years of expertise

More than
1.3
million patients treated worldwide

45
countries including the distribution network

Care Beyond Allergy

Four pillars form the framework of our corporate responsibility programme, *Care Beyond Allergy*. They emphasise our responsibility both as a company and as an employer and focus on areas in which we can make a difference: society, environment, social and governance.

Stallergenes Greer boasts a broad global footprint and extensive allergen and finished AIT product manufacturing capabilities.

ANTONY FRANCE
production of sublingual (solutions and tablets), and subcutaneous AIT products

AMILLY FRANCE
source materials (pollen) and securing of house dust mite strains

DUTTON ONTARIO CANADA
subcutaneous named patient products

LENOIR NORTH CAROLINA U.S.
source materials, sterile bulk allergenic extracts, compounding pharmacy and diagnostics

MATHISTON MISSISSIPPI U.S.
source materials (pollen)

SAN DIEGO CALIFORNIA U.S.
sterile bulk allergenic extracts, and contract manufacturing operations

6 manufacturing sites

1,194 employees worldwide

25 countries with a direct presence

Stallergenes Greer Foundation

The foundation's mission is "to create healthier futures for all" by: focusing on scientific research to bolster innovation and precision medicine; supporting academic initiatives to develop future generations of allergy healthcare professionals; and engaging in climate action and environmental protection to progress the prevention and treatment of allergies.



OUR PURPOSE

Enabling precision medicine to improve life for people with allergies.

OUR AMBITION

Becoming the world's leading allergen immunotherapy company.

OUR BUSINESS MODEL: CREATING VALUE

	HOW	FOR WHOM	
We have a direct presence in 25 countries	**GLOBAL FOOTPRINT**	**PATIENTS**	We innovate to improve their quality of life
We focus on precision medicine to shape the future of allergen immunotherapy	**RESEARCH & INNOVATION**	**HEALTHCARE PROFESSIONALS**	We support them with treatments that are adapted to the individual characteristics of their patient
We work with nature to develop safe, high-quality allergen immunotherapy treatments	**DEVELOPMENT**	**HEALTHCARE SYSTEMS**	We aim to provide better care and value by leveraging the full potential of precision medicine
We offer a comprehensive and consistent portfolio adapted to the individual needs and profile of each patient	**COMMERCIALISATION**	**COMMUNITIES**	We operate a sustainable organisation
An integrated approach driven by operational excellence	**MANUFACTURING & SUPPLY**	**EMPLOYEES**	We invest in our people and empower them to unleash their full potential
We continuously invest in innovation, facilities and people	**REINVESTING IN OUR BUSINESS CHAIN**	**SHAREHOLDER**	We deliver sustainable growth and profitability
		SUPPLIERS & PARTNERS	Our dedication to quality extends seamlessly to all our partners and service suppliers

OUR STRATEGY

Our strategy is designed to achieve our ambition of being the world's leading allergen immunotherapy (AIT) company for the long-term and deliver sustainable value to all our stakeholders: patients, the medical community, healthcare systems, colleagues and our shareholder.

> Delivering on our strategy

Launched in December 2019, the current strategy framework aims to transform Stallergenes Greer by ensuring profitability, fostering sustainable value, and driving long-term growth. Having achieved significant milestones, we are now set to enter a new growth phase to support our innovation ambitions within a 2030 timeframe.

Excellence in execution

Our ambition is to serve patients with high quality products and optimal solutions to treat allergies thanks to a robust supply chain and state-of-the-art pharmaceutical technologies.

- significant enhancement of our supply chain performance to increase competitiveness, improve responsiveness and operational flexibility and ensure the availability of our treatments

Strengthening our business

We aim to expand our geographical footprint, and we invest in areas where we can make a difference in the lives of people with allergies. We aim to offer physicians the broadest portfolio of allergens and delivery systems to foster precision medicine and deliver successful patient outcomes.

- opening of new affiliates
- launch of venom, peanut, house dust mite and grass pollen allergen immunotherapy treatments in new countries
- extension of indication of peanut oral immunotherapy to toddlers
- market share gains in many markets

Developing new solutions for our patients

For the benefit of patients across the globe, our objective is to further enrich the evidence of our treatments with new clinical and real-world data, improve treatment adherence with novel delivery tools, and discover and develop innovative products to treat respiratory, food and venom allergies.

- clinical and real-world studies advancing as per plan and delivering valuable new data
- successful implementation of iPUMP®, our connected AIT assistant in France

Attracting and developing talents

Our people are our greatest asset: they design, develop, and deliver solutions which are tailored to the individual needs and profile of patients. We invest in the development of our colleagues who are committed to improving the quality of life of allergy sufferers.

- employee capabilities strengthening through targeted training programmes
- development of a project management-driven culture aligned with strategy
- enhancement of workplace satisfaction, positioning the company as the right place to work and grow
- optimisation of recruitment to attract and retain top talent

EUROPE & INTERNATIONAL

DELIVERING THROUGH EXCELLENCE IN EXECUTION

With strong double-digit growth, 2024 was a year of success for the Europe and International region. Expansion was driven by the strengthening of our leadership position in more than 50% of the markets in which we operate, the extension of our geographic footprint and the enhancement of our portfolio.

GERMANY: A PILLAR OF GROWTH

In Germany, where Stallergenes Greer offers a fully registered evidence-based AIT (allergen immunotherapy) portfolio for key allergens, we maintained our position as the fastest-growing AIT company, both in terms of volume and new patients. Investments made over the past years to expand our sales force and intensify medical education initiatives have contributed to significantly increasing the Group's share of voice in the market.

DELIVERING VALUE

Because innovation in science is advancing at a rapid pace, our team of Medical science liaisons and Medical advisors across the region have expert knowledge of the clinical allergology landscape. They work with healthcare professionals to share scientific insight, data and facts to better cater to the needs of patients with allergies.

Focus, simplicity and excellence in execution guide our approach. Sales force effectiveness, which has been successfully implemented across the Group, plays a key role in improving the knowledge and skills of our sales force and gives us competitive edge.

BREAKING GROUND

In 2024, we expanded into the Nordic region with the establishment of an affiliate dedicated to Denmark, Norway and Sweden. In these markets, Stallergenes Greer now offers a fully registered portfolio of sublingual tablet treatments for grass pollen- (AitGrys®) and house dust mite- (AitMyte®) induced allergic rhinitis for the benefit of patients and the medical community. Our offering should be expanded to Finland in 2025.

New markets

Denmark
Norway
Sweden

The Nordics

PALFORZIA®, AN INCREASING REACH

Palforzia®, our oral immunotherapy (OIT) treatment, is currently available in six countries worldwide including France, US, Austria, Germany, Switzerland and the UK. The European rollout is expected to include the Netherlands in 2025. At year-end 2024, Palforzia® had posted double-digit growth both in volume and value in the region[2].

Building on this momentum, an important regulatory milestone was reached in December 2024: the European Commission approved the extension of indication of Palforzia® for the treatment of toddlers (ages 1 through 3) with a confirmed diagnosis of peanut allergy. The marketing authorisation covers all 27 European member states and the three European Economic Area states (Iceland, Liechtenstein and Norway).

Expanding our presence and portfolio

The year was also marked by the significant expansion of our portfolio and the improvement of market access conditions in several territories, notably in Eastern Europe, the Middle East and North Africa in the tablet and sublingual (SLIT) solution segments.

↘ IN POLAND

Staloral® house dust mite is now reimbursed for patients aged 12 to 18. We are working on the expansion to other age groups affected by house dust mite allergy as well as to achieve reimbursement status both for other Staloral® references and our tablet portfolio.

↘ IN RUSSIA

Where the market is undergoing a regularisation process, we continued to meet the market need.

↘ IN JAPAN

Thanks to a new commercial approach, patient initiation has accelerated.

↘ IN CHINA

The largest and fastest-growing market for AIT, we are continuing to execute our entry strategy as per plan.

↘ IN THE NETHERLANDS

Local payors have evaluated and recognised the value of our grass pollen tablet Oralair® which will improve patient access to our treatment option.

Strong double digit growth

1. Internal estimates.— 2. Based on internal data

Canada

In 2024, our Canadian team worked to strengthen its foundation. The affiliate achieved top-tier product turnaround times, redesigned its organisational structure and improved several of its operational systems. Work was also carried out with stakeholders to identify their challenges regarding allergen immunotherapy (AIT) to better cater to their needs.

Close to

400

allergens produced

In North America, Stallergenes Greer maintained leadership in the legacy bulk allergen business, made significant strides in the food allergy market and continued to invest in its operational infrastructure.

ADVANCING FOOD ALLERGY

A little over a year after having taken over Palforzia®, Stallergenes Greer has made significant advancements in the peanut allergy market. Its' North American Food Allergy business unit, with dedicated sales and commercial teams, has already extended Palforzia®'s prescriber base.

PALFORZIA®, APPROVED FOR TODDLERS

In July, the U.S. Food and Drug Administration approved the extension of indication of Palforzia® for the treatment of toddlers (ages 1 through 3) with a confirmed diagnosis of peanut allergy. Palforzia®, in combination with a peanut-avoidant diet, was launched for toddlers in early 2025.

NORTH AMERICA

DRIVING GROWTH AND RESILIENCE

RESPONDING TO HURRICANE HELENE

In September 2024, hurricane Helene, America's deadliest storm in almost two decades, heavily damaged seven southeastern states, including North Carolina where our Lenoir facility is based. In Lenoir, backup generators ensured uninterrupted operations despite temporary power loss and a rapid response team was implemented to protect our people and products for patients and provide assistance to customers who were able to quickly obtain their lost prescription and refilled allergen immunotherapy treatment.

Significant year-on-year growth in a declining market

Investing in our industrial operations

Because delivering high quality products, maintaining high compliance standards, and ensuring supply continuity for our customers are our priorities, we continued to invest in our operational infrastructure throughout the year. Investments are being made in advanced technology for aseptic manufacturing, such as restricted access barrier systems, as well as the introduction of new technology to improve our visibility into the supply chain and production flow.

GROWING AWARENESS OF ALLERGIES IN PETS

Our petsgetallergies.com website saw a surge in activity in 2024, reflecting the growing awareness and need for information on allergies in pets. Social media engagement flourished, with significant increases in views, reach and page visits. The video content offered helped raise awareness of the potential benefits of incorporating allergen specific immunotherapy (ASIT) in the management of allergies in pets.

100,000

total users in 2024 for www.petsgetallergies.com

ABOVE MARKET GROWTH IN ITALY AND SPAIN

Stallergenes Greer is well positioned in the ongoing regularisation process initiated by local health regulatory agencies and has submitted a wide portfolio of treatment and diagnostic product candidates for registration with pharmaceutical specialty status. In Italy, in line with our efforts to continuously improve access to treatment, health authorities have agreed to expand the reimbursement of Oralair® to all eligible patients. Stallergenes Greer Italy also launched Albey® venoms and obtained reimbursement of Palforzia®.



Orylmyte®
30% market share in France two years after launch

The Western and Southern Europe region (Belgium, France, Italy, Luxembourg, Spain) recorded a year of double-digit growth driven by positive market conditions, the strong impact of the lifecycle management of our products and the expansion of our portfolio with new launches across the countries.

HYMENOPTERA VENOM, FULFILLING A CRITICAL NEED

Stallergenes Greer launched Albey®, bee venom (Apis mellifera) and wasp venom (Vespula spp.), in France in July and in Italy in October. These treatments are listed by health authorities in the list of medicines of major therapeutic interest. According to the European Anaphylaxis Registry, these allergies are the most common cause of severe allergic reactions in adults (48.2%) and the second most common cause in children (20.2%) after food allergy[4].

WESTERN & SOUTHERN EUROPE

BREAKING GROUND TO ADDRESS EVOLVING NEEDS

IPUMP®, EASE OF USE AND ASSISTANCE IN AIT

We believe innovation starts by listening to patients. Because compliance to treatment is key to achieve long-term efficacy, Stallergenes Greer launched iPUMP® in France in October 2023, the first connected assistant in AIT, designed to improve treatment adherence and optimise outcomes for patients undergoing sublingual solution AIT treatment (SLIT solution). Less than a year after launching, iPUMP® was already used by more than 5,000 patients. Results of a retrospective real-life study[1] revealed that beyond its ability to secure the right gesture and reassure patients and parents, iPUMP® had a significant impact on treatment adherence: 82% of patients treated with iPUMP® continued their treatment after six months, versus 67% for non-users. This success is testimony to our commitment to combine patient insights and cutting-edge solutions

iPUMP® prescribed to more than 5,000 patients in France

MEETING EXPECTATIONS FOR CAT DANDER ALLERGY

Allergy to cat dander is the most common allergy to pets. Various studies have shown that the prevalence of sensitisation to cats is estimated at 5–20% of the global population and can be as high as 20–30% or more in patients with respiratory allergies[2].

Since its launch in 2021, Staloral® Cat 300 IR/mL has posted continuously increasing sales confirming an unmet medical need in the field of allergy to cat dander. Allergy to cat dander remains both undertreated and is less commonly treated with AIT, even though it can be more severe than other frequent allergies such as those induced by house dust mites or grasses[3]. To ensure continuous supply of this growing market segment, Stallergenes Greer has secured its raw material supply and built up a global multi-sourcing supply network.

ADRESSING PEANUT ALLERGY

Peanut is one of the most common triggers of food allergy and contributes to approximately 59% of fatal anaphylaxis caused by food allergies[5]. In France, Stallergenes Greer launched Palforzia®, our oral immunotherapy treatment (OIT), with the first patient initiations in July. At year-end, Palforzia® was already available in more than 15 hospitals across the country.

1. SPEED real-life study (conducted by AplusA for Stallergenes Greer, carried out between 29 May and 29 November 2024, based on an online questionnaire. The objective was to measure the impact perceived by patients, after 3 months of treatment with AIT, with the use of the iPUMP® connected assistant. 104 paediatric patients aged over 5 years and 77 adolescent and adult patients aged over 13 years). — 2. Sparkes AH. Human allergy to cats: A review for veterinarians on prevalence, causes, symptoms and control. J Feline Med Surg. 2022 Jan;24(1):31-42. — 3. A. Didier, L. Guilleminault, M. Migueres, C. Mailhol. Allergie au chat : une place pour la désensibilisation ? Revue française d'allergologie 63 (2023) 103284. — 4. Worm M, et al First European data from the network of severe allergic reactions (NORA). Allergy. 2014 Oct;69(10):1397-404. — 5. Bonku et al, Health aspects of peanuts as an outcome of its chemical composition. Food Science and Human Wellness 9 (2020) 21–30.

PEOPLE & CULTURE

The 1,194 colleagues of Stallergenes Greer are the foundation of the Group's success. Each day they work passionately to discover, develop and deliver high-quality allergy therapeutics for patients and healthcare professionals. In 2024, a variety of initiatives aimed at strengthening our culture, employee wellbeing and company attractiveness were implemented.



Taking the pulse

The wellbeing and engagement of our employees are our priority. In 2024, we launched a group-wide engagement survey, which reached a 68% participation rate and an overall satisfaction score of 7.3/10, to listen to our employees, identify our strengths and areas for improvement. The insights gained from the survey will be leveraged to develop targeted action plans designed to enrich our workplace culture and empower our teams.

7.3/10
overall satisfaction score

The values that guide us

The year was also dedicated to the redefinition of our corporate values. A team comprised of 13 colleagues, representing different departments and countries, worked together to develop values which reflect both the vision and experiences of colleagues and Stallergenes Greer's commitment to excellence, patient-centered innovation and ethics.

Our values form the bedrock of our company culture and behaviours and the principles we adhere to.

Respect
Accept and appreciate others for who they are, with kindness, courtesy and consideration.

Agility
The ability to adapt quickly to meet company objectives in a complex and changing environment.

Patient care
Accompanying and supporting allergic patients, guided by excellence, sharing and the commitment to improve their quality of life.

Integrity
Acting with honesty, ethics, loyalty and transparency, no matter the challenges or the obstacles.

Dedication Committing oneself with passion and involvement to the fulfilment of the company's mission, with a strong sense of purpose and always striving to surpass oneself.





Diversity, equity and inclusion

At Stallergenes Greer, we are committed to building a culture where all our employees feel welcomed, supported and valued for who they are regardless of ability, ethnicity, race, religion, culture, gender, gender identity, sexual orientation and age. Diversity, equity and inclusion (DEI) are at the heart of our talent retention, attraction and development policy.

As part of our ongoing efforts to promote DEI, during the European Week for the Employment of People with Disabilities, we organised a series of initiatives to raise awareness and tackle everyday challenges faced by persons with disabilities. Stallergenes Greer was privileged and honoured to welcome Gaël Rivière, Gold Medalist in Blind Football at the Paris 2024 Paralympic Games. During his conference, Gaël Rivière shared his experience and insights on inclusion, disability, handling pressure and achieving success through teamwork. It is through mutual respect and by building a culture of inclusion and empowerment that we can contribute to shaping a world where each individual can thrive.

In 2025, Stallergenes Greer will adopt a Group-wide DEI policy which will notably focus on key areas in which we strive for excellence: equal opportunity, gender equality, pay equity, workforce diversity.

49.8%

of women in management positions

68%

participation rate in engagement survey

2,123

hours of lean management and operational excellence training

Allergic to routine

We are committed to attracting, retaining and nurturing talent. Our employer branding campaign “Allergic to Routine”, rolled-out on social media during the year, highlights colleagues with different roles and positions who shared their enthusiasm and experiences about their work at Stallergenes Greer, while celebrating their achievements. Our inclusive recruitment and holistic approach to growth and development ensure a meaningful employee experience for all our colleagues.

GOVERNANCE

Board of Directors*

Stallergenes Greer is governed by a Board of Directors which is responsible for shaping and steering the strategic direction of Stallergenes Greer.

CYRUS JILLA
Chairman

MICHELE ANTONELLI
Chief Executive Officer

NITHYA DESIKAN
Director

GIAMPIERO DE LUCA
Director

RANJANI KEARSLEY
Director

Shareholding

Stallergenes Greer is a private company owned by interests associated with the Bertarelli family, which are advised by the B-FLEXION group.

B-FLEXION is a private, entrepreneurial investment firm, delivering exceptional value over the generations, while also contributing positively to society.

B-FLEXION continues to drive expansion by growing operating businesses in transformative industries. In keeping with – and building upon – its heritage, these are principally in the fields of life sciences, healthcare services and digital health.

Chaired by Ernesto Bertarelli, B-FLEXION has offices across Europe and in the U.S.

Executive Committee*

The Executive Committee, led by the Chief Executive Officer, is responsible for the management, development and performance of Stallergenes Greer.

From left to right: Dr Elena Rizova, *Chief Medical Officer* - Dominique Pezziardi, *President of Stallergenes SAS, Head of Western and Southern Europe* - Dr Michele Antonelli, *Chief Executive Officer* - Petr Tor, *Chief Commercial Officer* - Valérie Benhamou, *General Counsel* - Tibor Nemes, *Executive Vice President, Head of Americas* - Dr Julien Storaï, *Senior Vice President, Pharmaceutical Operations* - Nicola Lamacchia, *Chief Financial Officer* - Jérôme Tilly, *Senior Vice President, Human Resources*.

*At December 31, 2024

WHAT WE DO

BUSINESS ENVIRONMENT

The prevalence of allergic diseases has continued to rise steadily over the past 60 years in both developed and developing countries, and it is expected that by 2050 several billion people will suffer from allergies. Allergies represent a significant burden for patients and healthcare systems[1].

AIT: a modest proposal rate

The AIT (allergen immunotherapy) market is underdeveloped, representing approximately USD1.9bn. Market growth[2] should result from the rising prevalence of allergic conditions, increased awareness, improved access to allergists, growing healthcare spend and advancements in personalised treatment options. As more patients seek treatment for their allergies, the industry is gaining greater attention from the healthcare community.

ALLERGIC RHINITIS MARKET

USD11bn
(2023)
projected to grow at CAGR* of +5% by 2033[3]

AIT MARKET

USD1,5bn
(2023)
projected to grow at CAGR* of +5% by 2033[3]

FOOD ALLERGY MARKET

USD6.9bn
(2024)
projected to grow at a CAGR* of 8.27% by 2030[4]

Allergies, a significant economic burden

In the U.S. allergies are the sixth cause of chronic illness, with more than 50 million Americans experiencing allergies each year[1]. In Europe, more than 150 million people live with an allergic condition. In the European Union alone avoidable indirect costs for patients insufficiently treated for allergy range between €55 and €151 billion p.a. due to absenteeism and presenteeism[5].

Allergic rhinitis, a condition with underestimated consequences

Allergic rhinitis affects between 9-39% of the population worldwide* and symptoms have a significant impact on quality of life[6]. A less well-known, and often underestimated, consequence is that allergies put people at a greater risk of developing asthma. People with allergic rhinitis are three times more likely to develop asthma than other people, and the risk for patients with house dust mite-induced allergic rhinitis is about six times higher than for those whose allergic rhinitis is caused by grass pollen[7].

** compound annual growth rate*

1. EAACI Global atlas of Allergy 2014. — 2. https://www.towardshealthcare.com/insights/allergy-immunotherapy-market-sizing Last accessed January 24, 2025. — 3. Visiongain "Allergic Rhinitis Drugs Market Report 2023-2033" — 4. https://www.grandviewresearch.com/industry-analysis/food-allergy-treatment-market-report. Last accessed January 24, 2025. — 5. EAACI Advocacy Manifesto, version June 2015. — 6. Bousquet el al, Allergic Rhinitis Nature Reviews Disease Primers 2020 volume 6, 95. — 7. Aria Workshop Group; World Health Organization. Allergic rhinitis and its impact on asthma. J. Allergy Clin Immunol.2001 Nov;108(5 Suppl):S147-334

SHARING VIEWS

"When you discover that your two-year-old child is severely allergic to peanuts and nuts, you suddenly discover a world you never knew existed. Every meal, every snack, every moment spent outside the home becomes potentially dangerous.

Day nurseries, schools, activity centres... These places, which are supposed to be reassuring, are sources of anxiety because not everyone has the knowledge, or the tools, to react in case of an emergency. For parents, this means that we are constantly on our guard and live in fear of something happening.

I wanted to act so that children with food allergy could live more serenely and be integrated into society without their allergy becoming a hindrance to their development. I set up ALRJ and developed clothing and accessories to clearly identify their allergies and thus reduce everyday dangers.

But beyond prevention, what medical advances could change the daily lives of these children?"

FLAVIEN

Father of a child allergic to peanut and nuts

"The most challenging aspect of managing peanut allergy is knowing that most patients are not successful avoiding it, together with the fact that regardless of whether avoidance is successful, in early life most peanut allergy progresses to become a lifelong problem. However, building on our prior knowledge that peanut allergy in high-risk infants can be prevented with the early introduction of peanut, we now also realise that peanut allergic toddlers appear to respond to peanut oral immunotherapy better than older children."

STEPHEN TILLES

MD, Clinical professor of medicine at the University of Washington, Seattle, WA

Food allergy, a growing and underserved market

Food allergy affects approximately 4.3% of the general population but the spread of prevalence data is wide, ranging from 1% to 10%[1]. Peanut allergy is one of the major causes of severe life-threatening allergic reactions. The prevalence of food allergy is increasing each decade by 1.2% worldwide, mostly driven by environmental factors (e.g. pollution, urbanisation, hygiene hypothesis, etc.) and dietary factors associated with cultural/social behaviors (e.g., obesity, vitamin D deficiency, dietary fat, etc.)[2].

Insect venom allergy, the most common cause of severe anaphylaxis

Systemic-allergic sting reactions have been reported in up to 7.5% of adults and up to 3.4% of children[3]. Hymenoptera (honeybee, vespid, or ant) venom allergy is the most common trigger of severe anaphylaxis in adults[4]. As with respiratory allergy, climate change is also increasing the prevalence of venom allergy as the presence of stinging insects (such as Polistes) expands from Southern to Northern regions[5].

Around 30%

of the global population suffers from at least one allergic condition[6]

1. Bartha et al, Feast for thought: A comprehensive review of food allergy 2021-2023 J Allergy Clin Immunol 2024. — 2. Peters RL, et al An Overview of Environmental Risk Factors for Food Allergy. Int J Environ Res Public Health. 2022. — 3. Sturm GJ, et al, EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy. Allergy. 2018 Apr;73(4):744-764. — 4. Hymenoptera (bee and wasp) Stevens et al. Recent insights into the mechanisms of anaphylaxis. Curr Opin Immunol. 2023 Apr;81. —5. Vega et al, Impact of climate change on insect-human interactions. Curr Opin Allergy Clin Immunol. 2019 Oct;19(5):475-481. — 6. World Allergy Organization, Immunology and Biologics Symposium 2013. https://worldallergy.org/ symposium2013.

RESEARCH & DEVELOPMENT

For over a century, Stallergenes Greer has been committed to discovering, developing and delivering innovative allergen immunotherapy (AIT) diagnostic and treatment solutions to improve quality of life for people with allergies. We use cutting-edge technology and techniques to progress allergy research and care.

More than

10,500 patients

included in the Group's double-blind placebo controlled studies over 30 years

Precision medicine

Precision medicine is at the heart of our R&D strategy. Because the individual characteristics, etiology and mechanism of disease of each patient can impact response to the treatment, we focus our efforts on the clinical and molecular biology of disease to develop precise and personalised AIT treatments.

Supporting portfolio growth

Stallergenes Greer continued to grow its portfolio with the approval of Palforzia® for use in toddlers (ages 1 through 3) by the U.S. Food and Drug Administration in July 2024 and by the European Medicines Agency in December 2024.

Over

250 scientific studies

conducted since 1980

4.5/5

Allergy and immunotherapy Channel CME satisfaction rate

Evidence-based allergy care

In 2024, we finalised our **Practis** observational prospective study which evaluated the Patient Benefit index in over 700 patients undergoing sublingual AIT (SLIT) treatments and the link between adherence to treatment and treatment outcomes.

YOBI (YOung patients and BIrch allergy), our Phase III clinical trial to assess the safety and efficacy of Staloral® Birch in children and adolescents, is moving forward as planned and results are expected at the end of 2025.

The results of our **EfficAPSI** real-world evidence study, which included more than 110,000 patients treated with Staloral® and more than 330,000 controls, have been published in The Lancet Regional Health Europe. The study assessed the therapeutic benefits of sublingual liquid AIT treatment on the onset and worsening of asthma in patients with allergic rhinitis with or without asthma.

Bolstering innovation through collaborations

We continue to foster research collaborations to advance the understanding of the pathophysiology of allergic diseases and immune responses to AIT with world-class organisations, including Imperial College London (U.K.), the Swiss Institute of Allergy and Asthma Research (Davos, Switzerland), and Monash University and Alfred Hospital (Melbourne, Australia).

In 2024, we entered into a collaboration with the University of Katowice (Poland) to investigate the combined use of monoclonal antibodies (mAbs) and AIT in patients with allergy and asthma, aiming to gain further insight into the potential synergistic effects of this approach.

SHARING VIEWS

"Climate change, pollution, and urbanisation are altering the pattern of prevalence and severity of respiratory allergies.

Climate change affects pollen dynamics. With the rise in global temperature and CO_2 levels, the seasons of many allergenic plants are being extended and, in turn, increased CO_2 levels stimulate higher pollen production and the allergenic potency of the pollen itself.

Air pollution brings further complications by directly affecting respiratory health and interacting with allergens in ways that heighten their inflammatory potential.

Urbanisation adds another layer of complexity by changing microbial diversity and contributing to what some researchers refer to as the "biodiversity hypothesis." The decreased exposure to diverse microbes in urban environments may interfere with immune system development and tolerance, thereby increasing allergic sensitivity.

The exact mechanisms and interactions of these factors are a matter of continuing debate, however cumulative evidence points to environmental changes as critical contributors to the rising global burden of respiratory allergies. And this reality raises these questions: How can these environmental insights shape research strategies to tackle the changing profile of respiratory allergies? Can precision medicine be the answer to adapting treatments to the complexities of modern allergic diseases?"

DR SILVIA SCURATI

Therapeutic Area Medical Lead – Respiratory

DR LAURENT MASCARELL

Head of Innovation and science

"Promising avenues lie in integrating environmental data with AI-driven biomarker discovery and sero-epidemiological surveillance to better characterise individual patient profiles. By harnessing advanced analytics, we can identify previously unrecognised patterns and correlations between environmental exposures, immune system responses, and allergic disease manifestations.

Coupling cutting-edge data analytics with epidemiology allows for a deeper understanding of the increasingly complex landscape of modern allergic diseases which are shaped by a combination of genetic predispositions, environmental triggers, and lifestyle factors. This integrative approach not only enhances disease characterisation but also paves the way for the development of more precise and personalised strategies for patient care.

By leveraging these innovations, we can improve early detection, enhance therapeutic interventions, and empower patients with tailored and proactive allergy management solutions."

Accredited medical education

As part of our commitment to empower healthcare professionals with the latest medical knowledge and advancements in the field of allergy and AIT, we further developed our medical education efforts.

We supported via an unrestricted educational grant to MedScape an accredited medical education roundtable which brought together esteemed key external experts to discuss how to improve healthcare for respiratory allergies.

We also supported the "Allergy and Immunotherapy Channel", developed thanks to an unrestricted educational grant to Xpeer Medical Education, which hosts accredited educational modules for healthcare professionals. Available in five languages, the channel will cover topics such as AIT basics, adherence to AIT, as well as advanced modules.

Scientific excellence

Stallergenes Greer presented 21 abstracts at the 2024 European Academy of Allergy and Clinical Immunology (EAACI) of which three received awards.

We also enhanced our profile in the medical community with the strengthening of our scientific presence by deploying additional Medical Science Liaisons in key regions (France, the Netherlands, Poland, U.S.) to foster engagement with healthcare professionals.

21 abstracts

of which 3 received awards

Breakthrough scientific publications

Key articles were published in 2024 in leading allergy journals, e.g., Allergy, Journal of Allergy and Clinical Immunology, Clinical & Experimental Allergy and the Lancet Regional Health Europe covering various topics, including novel diagnostic approaches, predictive candidate biomarkers, the impact of AIT on allergic rhinitis and asthma control as well as asthma prevention.

TECHNICAL OPERATIONS

At Stallergenes Greer, we work with nature to produce high-quality allergen immunotherapy (AIT) treatments. Our Technical Operations focus on continuous improvement and lean management to consistently manufacture and deliver our AIT treatments and diagnostics to more than 1.3 million patients in 45 countries each year.

Expanding capacity

To meet the evolving needs of the allergy market, anticipate future demand and consistently ensure the efficient delivery of our treatments, the transformation of our Antony (France), Amilly (France) and Lenoir (U.S.) sites in 2024 continued throughout the year. In Antony, our production capacity increased significantly against the prior year, with volume growth for tablets and Staloral® reaching 20%.

State-of-the-art production assets

In Antony (France), a new automated packaging line for personalised Staloral® boxes is now operational and produces 30% of our packs. It enhances reliability, ensures uninterrupted supply and meets local pharmaceutical regulations. Our new tablet production line for Oralair® and Actair®/Orylmyte® is also progressively ramping up, thus securing supply continuity while delivering growing volumes.

Investments were also made to increase our active pharmaceutical ingredient production capacity for tablets which will begin operations in 2025.

In the U.S. notable investments this year include a 1-Megawatt generator with an uninterruptible power supply to safeguard production processes and materials, and a Restricted Access Barrier System ensuring effective protection for products, operators and the environment through advanced aseptic separation.

Operational excellence for a sustainable manufacturing platform

Ensuring the availability of high-quality treatments is a top priority for Stallergenes Greer. Throughout the year, we continued to invest in our industrial capability, practices and processes to continuously upgrade our infrastructure for the benefit of patients and healthcare professionals worldwide. A 5-year strategic industrial programme is in progress to bolster efficiency and leverage new technologies for the benefit of our customers. Investments include: the standardisation and automation of our supply chain to increase productivity and efficiency; process maximisation to strengthen and grow our production capacity; and cutting-edge production lines to improve the production flow.

50 million
tablets produced

Close to
2 tonnes
of house dust mite produced in Antony

4 tonnes
of cat hair collected globally, of which 100% of the dander is manufactured in the U.S.

5 million
vials of Staloral® produced

SHARING VIEWS

"The demand for AIT products has been growing steadily in Northern, Central and Eastern Europe driven by double-digit market growth along with market share uptake in most of the countries. On top of geographical expansion into new territories, such as the Nordics, we continue to strengthen our presence in established markets (e.g., Czech Republic, Slovakia), leveraging on market access changes in Poland and addressing new business opportunities in the Netherlands. The ability to respond quickly and effectively to market needs is critical. However, forecasting demand remains challenging due to factors like seasonality, requiring a high degree of flexibility and agility to adapt to fluctuations. Supporting patients and healthcare professionals with reliable product availability, tailored solutions, and resources to enhance patient care is central to our approach. How do we meet their needs, maintain high standards of quality and sustain our competitive edge?"

HANA HRUBA

VP Commercial Operations, Northern, Central and Eastern Europe

"We are dedicated to ensuring our supply chain efficiently meets increasing demand. Through close collaboration with our commercial teams, we have adopted advanced forecasting and supply planning tools to secure accurate forecasts and establish the required planning.

This approach minimises overproduction and shortages, while streamlined processes and protocols enhance collaboration. Improved inventory management further enables us to adapt to market fluctuations, building a resilient and agile supply chain that drives sustainable growth and operational excellence for high-quality patient solutions."

PATRICK PAULIN

Supply chain Director Europe and International

Leveraging our global strengths to address demand

Market expansion opportunities continue to drive demand for our products. To ensure supply continuity at Stallergenes Greer, we produce a large portion of the raw materials used to manufacture our AIT treatments. For example, our Mathiston (Mississippi) site in the U.S. is a major supplier of Mountain Cedar (Ashe Juniper) pollen for our Antony and Amilly production sites in France who then select the appropriate decontamination method based on analytical results. Mountain Cedar pollen is a critical cross-reactive substitute for Mediterranean Cypress (Cupressus sempervirens) in certain allergy treatments.



Supporting research for innovation

Characterisation is the cornerstone of both our research and innovation approach and our product manufacturing. Characterisation tests are used to understand the physical and chemical properties of biopharmaceutical substances. A state-of-the-art mass spectrometer enables us to support research for innovation, while catering to the requests of health authorities by raising assurance regarding our processes and our products thanks to the identification of all the allergens they may contain.

IMPACT



STALLERGENES GREER FOUNDATION

Innovating for healthier futures The Stallergenes Greer Foundation continues to champion innovation and patient-centered approaches, fulfilling its mission to “Create healthier futures for all.” The foundation, under the aegis of the Fondation de France, is dedicated to advancing allergy research, fostering academic excellence, and addressing environmental factors which impact allergies. With its commitment to excellence and innovation, the foundation bridges science, medicine and patient advocacy.

Science Awards for Allergy

In May 2024, the foundation announced the winners of the 2023 edition of its prestigious *Science Awards for Allergy*. Building on its success, the call for applications for the next edition was launched in early 2025.

The *Science Awards for Allergy* focus on innovation, patient empowerment, and treatment solutions which aim to improve the quality of life of individuals with allergies through personalised solutions, innovative research, and comprehensive care approaches.

The foundation will honour exceptional contributions by awarding a total of €150,000 in two categories:

- Innovation in Allergy Treatment Award: the award recognises cutting-edge research with clinical relevance in the field of allergy. It will support projects with practical outcomes and applications, which deepen knowledge of allergy treatments and inspire young researchers and clinicians. The award is expected to facilitate the implementation of innovative approaches in allergy care particularly in the areas of prevention, intervention and research.
- Patient Commitment Award: the award recognises projects which integrate the perspectives of patients with allergies, as well as those of their family, foster knowledge of allergic diseases and treatments, and develop the understanding of unmet needs to improve allergy care. The work must contribute to better understanding, preventing and treating respiratory or food allergy diseases.

Detailed information about eligibility, criteria, and the application process can be found on the foundation’s website: www.stallergenesgreer-foundation.org/

SHARING VIEWS

"Receiving this recognition from the foundation was deeply meaningful to me and my team.

Our research into mast cell biology, especially their role in allergic asthma, aims to unravel the complexities of these elusive immune cells. By identifying mast cell progenitors as potential biomarkers and therapeutic targets, we hope to pave the way for innovations that improve the lives of patients struggling with allergies and allergic asthma.

This award reinforces the importance of our work and inspires us to push the boundaries of discovery further by allowing to test new scientific ideas. It is truly inspiring to see such strong support for innovation in healthcare. I wish all future participants of the next edition the very best as they pursue their own groundbreaking research endeavours."

ASSOCIATE PROFESSOR DR JENNY HALLGREN MARTINSSON

Science Award Recipient, Senior Lecturer in Immunology, Department of Medical Biochemistry and Microbiology, Uppsala University, Sweden

DR ELENA RIZOVA

Member of the Managing Board of the Stallergenes Greer Foundation, Chief Medical Officer, Stallergenes Greer

"The groundbreaking research led by Dr Jenny Halgren Martinsson exemplifies the foundation's mission to foster innovation and drive patient-centered solutions in the field of allergy and immunology. Her discovery of mast cell progenitors as biomarkers represents a significant advancement in our understanding of the pathophysiology of allergic asthma and has the potential to transform both diagnostic and therapeutic approaches, offering new hope to millions of patients worldwide.

The numerous and high-quality applications received in 2024 are further testimony to the success of the foundation's mission to inspire and support transformative scientific achievements.

With this momentum, we are proud to launch the next edition of the awards, reaffirming our dedication to driving innovation in science that directly benefits patients and enhances clinical practice."

The foundation is guided by a dedicated leadership team and an international Scientific Board:

Managing Board

The Managing Board is composed of four Stallergenes Greer executive officers:

Dominique Pezziardi, Chairman of the Stallergenes Greer Foundation; Dr Elena Rizova, Scientific Director of the Stallergenes Greer Foundation; Dr Laurent Mascarell, Innovation Director of the Stallergenes Greer Foundation, Catherine Kress, Secretary General of the Stallergenes Greer Foundation.

Scientific Board

The Scientific Board is composed of four independent members:

Pascal Demoly, Professor of Pulmonology and Head of Department at the University Hospital of Montpellier (France); Alessandro Fiocchi, MD, Director of Allergy at Pediatric Hospital Bambino Gesù, Rome, Vatican City (Italy); Carla Irani, Associate Professor, Internal Medicine and Clinical Immunology, Allergology - Immunological Asthma at Hôtel Dieu de France University Medical Center, Beirut (Lebanon); Kari Nadeau, MD, PhD, Chair of the Department of Environmental Health at Harvard T.H. Chan School of Public Health, Boston (MA, U.S.)

CARE BEYOND ALLERGY

SOCIETY

“Patient needs drive our innovation to fight against all kinds of allergies”

ENVIRONMENT

“We are committed to advancing climate action and preserving nature to boost the prevention and treatment of allergies”

SOCIAL

“Investing in our people and empowering them to unleash their full potential”

GOVERNANCE

“Building trust with our stakeholders every day”

Driving sustainability

After having defined Stallergenes Greer’s corporate responsibility ambitions and set measurable targets for our Care Beyond Allergy programme, we are entering a more operational phase as we work toward compliance with the Corporate Sustainability Reporting Directive (CSRD), the new European non-financial reporting framework.

In 2024, we notably carried out a double materiality assessment on the non-financial reporting areas as defined by the CSRD to assess how our company’s actions affect broader sustainability issues. Impact materiality (to analyse the impact of the company’s activities on the environment and society) and financial materiality (to analyse and assess environmental, social and governance issues on the company’s economic and financial performance in terms of risks and opportunities) assessments were accomplished.

To carry out these assessments, contributor groups were set up to:

- identify categories of stakeholders (building on the results of the study carried out in 2022) who could be affected by the company’s activities,
- put into perspective the sustainability challenges of our industrial sector,
- take into account the investment needs related to the transition to more sustainable production.

Using the method defined by EFRAG, 28 sustainability challenges (8 relating to the environment, 15 to social and 5 to governance) were identified and screened. The impacts, risks and opportunities of each challenge were analysed to determine the level of materiality for Stallergenes Greer and thus condition our future reporting requirements.

The final matrix will be audited by an external institution and shared with the publication of the first report.

CORPORATE RESPONSIBILITY ASSESSMENTS OF OUR ACTIVE SUPPLIERS Stallergenes Greer has partnered with Ecovadis to screen the company’s suppliers. 250 suppliers have already been approached for a detailed assessment of the corporate responsibility commitments and 610 suppliers will have been screened by the end of 2025.

DECARBONATION An assessment of our carbon footprint was carried out in 2023 and updated in 2024 to include Stallergenes Greer’s U.S. operations which must be taken into account for our Group decarbonation strategy.

Stallergenes Greer's 12 key performance indicators provide an objective and transparent basis for measuring progress toward our 2030 corporate responsibility ambition. 2024 marks the first year of reporting on these KPIs which reflect our commitment to sustainability. Regarding our use of natural resources, we are continuing work with external experts to define reduction trends such as those pertaining to greenhouse gas (GhG) emissions.

SOCIETY

2030 AMBITION	KPI MEASURED AT YEAR END 2024
Extend access to, and use of, Stallergenes Greer AIT products	8 active educational programmes either sponsored or supported by unrestricted educational grants: • EAACI: 4 modules, AIT module, New insights in AIT module, 2 MOOC on OMIC technologies in allergy research, • Karger, accredited CME course on the use of AIT in respiratory allergy, • Xpeer, accredited CME course on AIT basics, • Medscape, accredited CME roundtable on how to identify patients in need of AIT and optimise patient outcomes, • Go Beyond AIT training programme 10 publications and 21 abstracts More than 1.3 million patients treated with Stallergenes Greer products
Increase the production capacity of our new sublingual specialty production line each year	Automated packaging line in Antony (France) packaged 50% of total SLIT vials, 100% of which are for export
Empower patients by integrating their voice in our initiatives	Three surveys/studies led with patient community: • Online cat SLIT treatment survey in France to gain understanding of socio-demographic characteristics, living environment and cat exposure, allergy history and management, and perception of SLIT impact. 197 responders • 45-minute interviews with 15 patients/caregivers in the U.S. to understand attitudes, experiences and unmet needs with respect to SCIT treatment • SPEED survey in France for patients undergoing cat or house dust mite AIT, with or without using iPUMP®, regarding proper use and observance (400 patients)

ENVIRONMENT

2030 AMBITION	KPI MEASURED AT YEAR END 2024
Ensure that volume growth until 2030 will be delivered by reaching efficiencies on water consumption at the Antony and Lenoir sites	Water consumption at the Antony and Lenoir sites has been measured, and reduction levers are being explored
Reduce our GhG emissions (scope 1, 2, 3) compared to baseline	Assessment of our 2023 GHG emissions: 19,983 tCO2e across France and the US. Our carbon transition plan is in progress
An eco-friendly pack pilot for sublingual specialty available for implementation in manufacturing by 2025	In progress. The pilot is expected to be available by year-end 2025

SOCIAL

2030 AMBITION	KPI MEASURED AT YEAR END 2024
Maintain the injury frequency rate at less than or equal to 3.5%	Injury frequence rate at year-end 2024: 3.47%
Increase every other year employee satisfaction as measured by wellbeing survey	2024 wellbeing survey: • Participation rate: 68% • Employee satisfaction rate: 73%
100% of employees will have followed training and e-learning annually (excluding mandatory trainings by law) by 2030	2024: 97% (96% in 2023)
Include all employees in people review program	All group Executive Committee members and senior leaders included in the People review process

GOVERNANCE

2030 AMBITION	KPI MEASURED AT YEAR END 2024
100% of key third parties considered as critical from a compliance standpoint will be assessed for their integrity in conducting business	40% of third parties screened in 2024
Expand each year the coverage of corporate responsibility assessments of our active supplier database	• 99% of active suppliers assessed using the Ecovadis IQ-Plus module • Onboarding of 250 suppliers with the RATING module

PRODUCTS & PORTFOLIO

OUR PRODUCTS

Stallergenes Greer supports physicians specialised in allergy and patients at each stage of allergen immunotherapy (AIT) treatment. Our comprehensive and consistent portfolio is adapted to the individual needs and profile of each patient and covers a broad variety of allergens.

Spanning source materials, routes of administration, cutting-edge delivery mechanisms and finished products, Stallergenes Greer's innovative diagnostic tools and AIT solutions are designed to improve ease of access and treatment outcomes.

Whatever the options, Stallergenes Greer's diagnostic and AIT treatments meet the most stringent clinical criteria, quality standards and health authorities' regulatory requirements.

A personalised and standardised treatment offering

Stallergenes Greer believes one solution does not fit all patients, hence we provide patients with personalised treatment options that are tailored to their individual needs. We aim to offer a comprehensive portfolio of AIT treatments globally which allow patients and their physicians to determine the administration method that best meets the disease and lifestyle needs of the patient.

The Group's allergen extracts cover a vast array of allergens. They can be produced in standardised form and can also be tailored to the specific needs of patients in terms of composition, concentration, and dosage. These personalised solutions, known as named patient products (NPPs), are prepared according to the physician's prescription and the patient profile using a stock solution obtained via the extraction of allergens (pollens, house dust mites, moulds...). Each NPP has its own biological activity and is prepared for the unique needs of the individual patient.

Respiratory allergy

SUBLINGUAL

Staloral® (oral solution), for the treatment of allergy involving rhinitis, conjunctivitis, rhino conjunctivitis or asthma (mild to moderate) of a seasonal or perennial nature, in adults and children (from the age of 5).

Actair®/ Orylmyte®/ Aitmyte® (tablet), for the treatment of house dust mite allergies involving rhinitis, with or without conjunctivitis, in adults and adolescents over the age of 12 (and under 12 years of age in certain territories).

Oralair®/ Aitgrys® (tablet), for the treatment of grass pollen allergic rhinitis with or without conjunctivitis in adults, adolescents, and children (above the age of 5). Oralair® is a five grass (cocksfoot, sweet vernal grass, rye grass, meadow grass, and timothy) mixture, which represents many of the natural exposure and sensitisation conditions of grass pollen allergic patients.

SUBCUTANEOUS

Alustal®, for the treatment of allergic rhinitis, allergic rhinoconjunctivitis or mild to moderate asthma in adults and children (from the age of 5).

Food allergy

ORAL IMMUNOTHERAPY

Palforzia®, for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut for patients aged 1 to 17 years with a confirmed diagnosis of peanut allergy. Use of Palforzia® may be continued in patients 18 years of age and older. Palforzia® is not indicated for the emergency treatment of allergic reactions, including anaphylaxis, and must always be used in conjunction with a peanut-avoidant diet.

Venom allergy

SUBCUTANEOUS

Albey® venom, for the treatment of allergy to wasp, honeybee and yellow jacket venoms.

Veterinary use

From allergen testing to making precision treatment medicines, Stallergenes Greer is committed to providing veterinary specialists with products that can help treat animal allergies.

In the U.S., Stallergenes Greer offers a comprehensive range of allergen extracts and supplies for veterinary dermatologists to support the needs of their clients and pet patients.

Veterinary dermatologists are veterinarians that have specialised training in the management of allergic disease. They may use products from companies like Stallergenes Greer to compound named patient allergy products for dogs, cats, horses, and more. Stallergenes Greer produces extracts of different strengths and formulations specifically for veterinary specialists.

Extracts and supplies

Stallergenes Greer manufactures a broad portfolio of allergen extracts and diagnostic tests.

Connected assistant

iPUMP® designed to improve treatment adherence and optimise outcomes for patients undergoing sublingual solution AIT treatment.

Not all our products and extracts are available in all geographic territories.

OUR PORTFOLIO

1/ SUBLINGUAL PRODUCTS

The allergens and concentrations available vary by market.

Allergens:

MITES
D.pteronyssinus
D. Farinae
D.pte / D.far 50/50
Blomia / D.pte / D.far

GRASSES
5 Grasses
Cocksfoot
Timothy
Bermuda Grass

TREES
Birch
Ash
Alder
Hazel
Olive
2 Trees Mix (Ash / Olive)
3 Trees Mix
(Alder / Birch / Hazel)
Cupressaceae
Birch / Timothy Mix

DANDER
Cat epithelia
Cat IR300

WEEDS
Ragweed
Wall pellitory
Mugwort

MOULDS
Alternaria

POLLEN MIX
Birch / Ash
5 Grasses / Olive
5 Grasses / Birch
5 Grasses / Rye
5 Grasses / Juniperus
5 Grasses / Ash
5 Grasses / Berm. Grass
5 Grasses / 3 trees
5 Grasses / Ragweed
Birch / Timothy
Olive / Ash
Cupressaceae / Olive
Birch / Olive
Ragweed / Mugwort
5 Grasses / Mugwort
5 Grasses / Cynodon

ORALAIR® / AITGRYS®

A five grass pollen mixture composed of Cocksfoot *(Dactylis glomerata L.)*, Sweet vernal grass *(Anthoxanthum odoratum L.)*, Rye grass *(Lolium perenne L.)*, Meadow grass *(Poa pratensis L.)* and Timothy *(Phleum pratense L.)*.

2/ ORAL IMMUNOTHERAPY

PALFORZIA®

A defatted powder of *Arachis hypogaea* L., semen (peanuts).

3/ SUBCUTANEOUS PRODUCTS

ALUSTAL®

ALBEY VENOM®*

4/ VETERINARY PRODUCTS

VET EXTRACTS

Allergens:

TREES & SHRUBS
Acacia
Alder, Hazel
Alder, Red
Alder, White
Ash, Arizona
Ash, Oregon
Ash, Red/Green
Ash, White
Aspen
Bayberry/Was Myrtle
Beech, American
Birch, Black/Sweet
Birch, River
Birch, Spring
Birch, White
Box Elder
Cedar, Mountain
Cedar, Red
Cedar, Salt/Tamarisk
Cottonwood, Black
Cottonwood, Eastern
Cottonwood, Fremont
Cottonwood, Western
Cypress, Arizona
Cypress, Bald
Elm, American
Elm, Cedar/Fall Blooming
Elm, Siberian
Eucalyptus
Hackberry
Hazelnut, American
Hickory, Shagbark
Hickory, Shellbark
Hickory, White
Juniper, Oneseed
Juniper, Pinchot
Juniper, Rocky Mountain
Juniper, Utah
Juniper, Western
Locust Blossom, Black
Mango Blossom
Maple, Red
Maple, Silver/Soft
Maple, Sugar/Hard
Melaleuca
Mesquite
Mulberry, Paper
Mulberry, Red
Mulberry, White
Oak, Arizona/Gambel
Oak, Black
Oak, Bur
Oak, California Black
Oak, California Live
Oak, California White
Oak, Post
Oak, Red
Oak, Virginia Live
Oak, Water
Oak, Western White
Oak, White
Olive
Olive, Russian
Orange Pollen
Palm, Queen
Pecan
Pepper Tree
Pine, Australian (Beefwood)
Pine, Loblolly
Pine, Longleaf
Pine, Ponderosa
Pine, Virginia/Scrub
Pine, Eastern White
Pine, Western White
Pine, Yellow
Poplar, Lombardy
Poplar, White
Privet, Common
Sweet Gum
Sycamore, American/ Eastern
Sycamore, Western
Walnut, Black
Walnut, California Black
Walnut, English
Willow, Arroyo
Willow, Black
2 Maple Mix
3 Maple Mix
11 Tree Mix
Ash Mix
Birch Mix
Eastern 6 Tree Mix
Eastern 7 Tree Mix
Eastern 8 Tree Mix
Eastern 10 Tree Mix
Eastern Oak Mix
Elm Mix
Hickory Mix
Hickory-Pecan Mix
Maple-Box Elder Mix
Pine Mix
Western 10 Tree Mix
Western Oak Mix
Western Walnut Mix
Daisy Ox-Eye
Dandelion
Sunflower
Alfalfa
Mustard
Red Clover
Sugar Beet

WEEDS
Allscale
Baccharis
Burrobrush
Careless Weed, Amaranth/ Green
Cocklebur
Dock, Yellow/Curly
Dog Fennel
Firebush/Kochia
Goldenrod
Hemp, Water
Iodine Bush
Lambs Quarter
Lenscale/Quailbrush
Marsh Elder, Burweed/Giant Poverty
Marsh Elder, True/Rough
Mugwort, Common
Mugwort, Darkleaved/ Sagebrush, Prairie
Nettle
Palmer's Amaranth
Pigweed, Rough/Redroot
Plantain, English
Rabbit Bush
Ragweed, Desert
Ragweed, False
Ragweed, Giant
Ragweed, Short
Ragweed, Slender
Ragweed, Southern
Ragweed, Western
Russian Thistle
Sagebrush, Common
Saltbush, Annual
Sorrel, Sheep/Red
Wingscale
3 Weed Mix
Dock-Sorrel Mix
Pigweed Mix
Plantain-Sorrel Mix
Ragweed Mix
Sage Mix
Scale/Atriplex Mix
Western Ragweed Mix

GRASSES
Bahia Grass
Bermuda
Brome Grass, Smooth
Canarygrass
Corn, Cultivated
Couch/Quack Grass
Johnson Grass
Kentucky Blue/June
Meadow Fescue
Oats, Common/Cultivated
Orchard
Redtop

RYE, CULTIVATED
Ryegrass, Giant Wild
Ryegrass, Italian
Ryegrass, Perennial
Sweet Vernal
Timothy
Velvetgrass
Wheat Cultivated
Wheatgrass, Western
7 Grass Mix
9 Southern Grass Mix
Bermuda-Johnson Grass Mix
K-O-R-T Grass Mix

FUNGI & SMUTS
Acremonium strictum
Alternaria alternata
Aspergillus amstelodami
Aspergillus flavus
Aspergillus fumigatus
Aspergillus nidulans
Aspergillus niger
Aureobasidium pullulans
Bipolaris sorokiniana
Botrytis cinerea
Candida albicans
Chaetomium globosum
Cladosporium herbarum
Cladosporium sphaerospermum
Drechslera spicifera
Epicossum nigrum
Epidermophyton floccosum
Fusarium moniliforme
Fusarium solani
Geotrichum candidum
Gliocladium viride
Helminthosporium solani
Malassezia pachydermatis
Mucor circinelloides f. circinelloides
Mucor circinelloides f. lusitanicus
Mucor plumbeus
Neurospora intermedia
Paecilomyces variotii
Penicillium chrysogenum (notatum)
Penicillium digitatum
Phoma betae
Rhizopus oryzae
Rhizopus stolonifer
Rhodotorula mucilaginosa
var. mucilaginosa
Saccharomyces cerevisiae
Stemphylium solani
Trichoderma harzianum
Trichophyton mentagrophytes
Trichophyton rubrum
Trichothecium roseum
Aspergillus Mix
Dematiaceae Mix
Fusarium Mix
Mold Mix #1
Mold Mix #2
Mold Mix #3
Monilia Mix
Mucor mix
Penicillium Mix
Phycomycetes Mix
Rhizopus Mix
Corn Smut
Grain Smut mix
Grass Smut Mix

EPITHELIA
Cat Epithelia
Cattle Epithelia
Dog Epithelia
Gerbil Epithelia
Goat Epithelia
Guinea Pig Epithelia
Hamster Epithelia
Hog Epithelia
Horse Epithelia
Human Dander
Mouse Epithelia
Rabbit Epithelia
Rat Epithelia
Sheep Epithelia

FEATHERS & MISCELLANEOUS INHALANTS
Canary Feathers
Chicken Feathers
Duck Feathers
Parakeet Feathers
Feather Mix
Cotton Linters
Cottonseed
Flaxseed
Kapok Seed
Orris Root
Pyrethrum
Silk
Tobacco Leaf

INSECTS
Ant, Black/Carpenter
Ant, Fire – Solenopsis richteri
Ant, Fire – Solenopsis invicta
Cockroach, American
Cockroach, German
Culicoids
Deer Fly
Flea
Horse Fly
House Fly
Mosquito
Moth
2 Cockroach Mix
4 Insect Mix

DUST & DUST MITES
Dust, House
Grain Mill Dust Mix
Acarus siro
Blomia tropicalis
Dermatophagoides farinae
Dermatophagoides pteronyssinus
Lepidoglyphus destructor
Tyrophagus putrescentiae
Equal Parts Mixture

VET OTHER SUPPLIES

STERILE DILUENTS

NONSTERILE EMPTY VIALS

STERILE EMPTY VIALS

PLASTIC COLORED CAPS

VIAL RACKS

AMBER VIALS AND METERED PUMPS

SYRINGES AND SYRINGE TRAYS

ANCILLARY PRODUCTS

5/ STANDARDISED HUMAN EXTRACTS

STANDARDISED CAT HAIR

STANDARDISED DERMATOPHAGOIDES FARINA MITE

STANDARDISED DERMATOPHAGOIDES PTERONYSSINUS MITE

STANDARDISED MITE MIX

STANDARDISED GRASS & POLLENS
Bermuda Grass
Kentucky Blue/June
Meadow Fescue
Orchard
Redtop
Ryegrass, Perennial
Sweet Vernal
Timothy
7 Grass Mix
K-O-R-T Grass Mix
K-O-R-T and Sweet Vernal Mix
K-O-T Grass Mix
Timothy/Orchard Grass Mix
T-O-S Grass Mix
Ragweed, Short
National Weed Mix
Ragweed Mix

POLLENS -TREES & SHRUBS
Acacia
Alder, Hazel
Alder, Red
Alder, White
Ash, Arizona (Velvet)
Ash, Green
Ash, Oregon
Ash, White
Aspen
Beech, American
Birch, Black/Sweet
Birch, River
Birch, Spring
Birch, White
Box Elder
Cedar, Mountain
Cedar, Red
Cedar, Salt (Tamarisk)
Cottonwood, Arizona (Fremont)
Cottonwood, Black
Cottonwood, Eastern
Cottonwood, Western
Cypress, Arizona
Cypress, Bald
Elm, American
Elm, Cedar
Elm, Siberian
Eucalyptus, Bluegum
Hackberry
Hazelnut, American
Hickory, Shagbark
Hickory, Shellbark
Hickory, White
Juniper, Oneseed
Juniper, Pinchot
Juniper, Rocky Mountain
Juniper, Utah
Juniper, Western
Locust Blossom, Black
Mango Blossom
Maple, Red
Maple, Silver/Soft
Maple, Sugar/Hard
Melaleuca
Mesquite, Velvet
Mulberry, Paper
Mulberry, Red
Mulberry, White
Oak, Arizona (Gambel)
Oak, Black
Oak, Bur
Oak, California Black
Oak, California Live
Oak, California White
Oak, Post
Oak, Red
Oak, Virginia Live
Oak, Water
Oak, Western White
Oak, White
Olive
Olive, Russian
Orange Pollen
Palm, Queen
Pecan
Pine, Australian (Beefwood)
Pine, Loblolly
Pine, Longleaf
Pine, Ponderosa
Pine, Virginia Scrub
Pine, Eastern White
Pine, Western White
Pine, Yellow
Poplar, Lombardy's
Poplar, White
Privet
Sweetgum
Sycamore, American
Sycamore, California (Western)
Walnut, Black
Walnut, California Black
Walnut, English
Wax Myrtle
Willow, Arroyo
Willow, Black
2 Maple Mix
3 Maple Mix
11 Tree Mix
Birch Mix
Central/Eastern 4 Tree Mix
Eastern 6 Tree Mix
Eastern 7 Tree Mix
Eastern 8 Tree Mix
Eastern 9 Tree Mix
Eastern 10 Tree Mix
Eastern Oak Mix
Elm Mix
Hickory Mix
Hickory-Pecan Mix
Juniper Mix
Maple-Box Elder Mix
Peppertree Mix
Pine Mix
Western 3 Tree Mix
Western 10 Tree Mix
Western Oak Mix
Western Walnut Mix

POLLENS – FLOWERS & PLANTS
Daisy
Dandelion
Sunflower
Alfalfa
Rape (Mustard)
Red Clover
Sugar Beet

POLLENS - WEEDS
Allscale
Amaranth, Green
Burningbush (Kochia)
Burrobrush
Cocklebur
Dock, Yellow (Curly)
Dogfennel
Goldenrod
Iodinebush
Lamb's Quarters
Lenscale (Quailbrush)
Marshelder, Burweed (Giant Poverty)
Marshelder, True (Rough)
Mugwort, Common
Nettle
Palmer's Amaranth
Pigweed, Rough Redroot
Pigweed, Spiny
Plantain, English
Rabbit Bush
Ragweed, Desert
Ragweed, False
Ragweed, Giant (Tall)
Ragweed, Lanceleaf
Ragweed, Slender
Ragweed, Western
Russian Thistle
Sagebrush, Common
Sage, Prairie
Saltbush, Annual
Sorrel, Sheep (Red)
Waterhemp, Tall
Wingscale
3 Weed Mix
Baccharis Mix
Central/Western Weed Mix
Common Weed Mix
Dock-Sorrel Mix
Pigweed Mix
Plantain-Sorrel Mix
Sage Mix
Scale/Atriplex Mix
Western Ragweed Mix

POLLENS - GRASSES
Brome, Smooth
Canary Grass, Reed
Corn, Cultivated
Johnson Grass
Oats, Cultivated
Quack (Couch) Grass
Rye, Cultivated
Ryegrass, Giant Wild
Ryegrass, Italian
Velvetgrass
Wheat, Cultivated
Wheatgrass, Western

MOULDS
Alternaria alternata
Aspergillus amstelodami
Aspergillus flavus
Aspergillus fumigatus
Aspergillus nidulans
Aspergillus niger
Aureobasidium pullulans
Bipolaris sorokiniana
Botrytis cinerea
Candida albicans*
Chaetomium globosum
Cladosporium herbarum
Cladosporium sphaerospermum
Curvularia spicifera
Epicossum nigrum
Epidermophyton floccosum
Fusarium solani
Geotrichum candidum
Gibberella fujikuroi
Gliocladium viride
Helminthsporium solani
Hypomyces perniciosus
Microsporum canis
Mucor circinelloides f. circinelloides
Mucor circinelloides f. lusitanicus
Mucor plumbeus
Neurospora intermedia
Paecilomyces variotii
Penicillium chrysogenum var. chrysogenum
Penicillium digitatum
Phoma betae
Rhizopus arrhizus
Rhizopus stolonifer
Rhodotorula mucilaginosa
Saccharomyces cerevisiae
Sarocladium strictum
Stemphylium solani
Trichoderma harzianum
Trichophyton mentagrophytes
Trichophyton rubrum
Trichothecium roseum
AHH Mix
Alternaria/Hormodendrum Mix
Aspergillus Mix
Dematiaceae Mix
Fusarium Mix
Mold Mix #1
Mold Mix #2
Mold Mix #3
Monilia Mix
Mucor Mix
New Stock Fungi Mix
Penicillium Mix
Phycomycetes Mix
Rhizopus Mix
Bermuda Grass Smut
Corn Smut
Loose Smut of Barley
Loose Smut of Wheat
Oat Smut
Grain Smut Mix
Grass Smut Mix

EPITHELIA
Cattle Epithelia
Dog Epithelia
Gerbil Epithelia
Goat Epithelia
Guinea Pig Epithelia
Hamster Epithelia
Hog Epithelia
Horse Epithelia
Mouse Epithelia
Rabbit Epithelia
Rat Epithelia
Canary Feathers
Chicken Feathers
Duck Feathers
Parakeet Feathers
Feather Mix
Cotton Linters
Cottonseed
Flax
Gum Arabic
Gum Karaya
Gum Tragacanth
Kapok
Leaf Tobacco, Cultivated
Orris Root
Pyrethrum
Silk Worm Cocoon
Ant, Black Carpenter
Fire Ant – Solenopsis richteri
Fire Ant – Solenopsis invicta
Cockroach, American*
Cockroach, German*
Deer Fly
Flea (Aqueous Only)
House Fly
Mosquito
2 Cockroach Mix

FOODS
Apple
Apricot
Banana
Barley, Whole Grain
Bean, Lima
Bean, Navy
Bean, String Green
Blueberry, Velvetleaf
Broccoli
Buckwheat
Cabbage
Cantaloupe
Carrot
Cauliflower
Celery
Cherry, Sweet
Cacao Bean
Cinnamon
Coffee
Corn
Cranberry
Cucumber
Garlic
Ginger
Grape, White Seedless
Grapefruit
Hops
Lemon
Lettuce
Malt
Mushroom
Mustard Seed
Nutmeg
Oat
Olive, Green
Onion
Orange
Pea, Green or English
Peach
Pear
Pepper, Black
Pepper, Green
Pineapple
Potato, Sweet
Potato, White
Raspberry, Red
Rice
Rye
Sesame Seed
Soybean
Spinach
Squash, Yellow Summer
Strawberry
Tomato
Vanilla
Watermelon
Wheat, Whole
Beef
Lamb
Pork
Chicken Meat
Egg White, Chicken
Egg Whole, Chicken
Egg Yolk, Chicken
Turkey Meat
Milk, Cow
Bass, Black
Catfish, Channel
Clam, Northern Quahog
Cod, Atlantic
Crab, Blue
Flounder, Southern
Lobster, American
Mackerel, King/Atlantic
Oyster, Atlantic/Eastern
Perch, Ocean
Salmon, Atlantic
Scallops, Sea
Shrimp, Brown
Trout, Rainbow
Tuna, Yellowfin
Fish, Mix
Shellfish Mix
Almond
Brazil Nut
Cashew Nut
Coconut
Hazelnut (Filbert)
Peanut
Pecan
Walnut, Black
Walnut, English

5/ PRICK TESTS

40-WELL SKIN OMNI™ EVALUATION PACKAGE

40-WELL GREER® PICK® EVALUATION PACKAGE

60-WELL SKIN OMNI™ EVALUATION PACKAGE

60-WELL GREER® PICK® EVALUATION PACKAGE

ALYOSTAL PRICK ®

Positive control (Histamin)
Negative control
D. Pteronyssinus
D. Farinae
5 Grasses
Birch
Ragweed
Hazel
Olive
Cupressacee
Cat dander
Mugwort
Alder
Ash
Wall pellitory
Blomia
Cynodon
Rye grass
Alternia
Artemisia
Bermuda grass
Latex

GREER® PICK®

GREER® PICK® TRAY™

GREER® PICK® TRAY™

LID PRICK LANCET®

STALLERPOINT®

GREER® PICK® WELL™

SKINTESTOR OMNI™

SKINTESTOR OMNI™ SYSTEM

SKINTESTOR OMNI™ TRAYS

THE GREER® PICK® SYSTEM

6/ OTHER SUPPLIES

DOM' HOUS®

GREER® STERILE DILUENTS™

GREER® STERILE EMPTY VIALS™

GREER® VERSA VIAL RACK

ANCILLARY PRODUCTS

GREER PHARMACY – NAMED PATIENT PRODUCTS

IPUMP®

JIFFY MAILING BAGS

MAILING CONTAINERS

NONSTERILE EMPTY VIALS

PLASTIC COLOURED CAPS

SAFETY SYRINGES STERILE DILUENTS

SHARPS COLLECTORS

SKIN REACTION GUIDES

STERILE EMPTY VIALS

STOCK AND CUSTOM-PRINTED LABELS

STYROFOAM CONTAINERS

SYRINGES AND SYRINGE TRAYS

VIAL RACKS

Not all of our products and extracts are available in all geographic territories.

** Progressive resumption of production*

STALLERGENES GREER
INTERNATIONAL AG
Zugerstrasse 76b
6340 Baar, Switzerland

This report contains information about Stallergenes Greer's worldwide business. Information concerning pharmaceuticals and medical devices (including compounds under development) contained herein is not intended as advertising or as medical advice.

2024 In Review is available on the Group's website **www.stallergenesgreer.com**

CONCEPTION AND EDITORIAL FOLK FORMAN, 68 rue de la Chaussée d'Antin, 75009 Paris, FRANCE
www.folkforman.com

CREATION AND PRODUCTION MPG VISUAL DESIGN, PO Box 1002, Manzanita, OR 97130, USA
www.mpgvisualdesign.com

PHOTO CREDITS All rights reserved - Anthony Voisin (cover, p 3, 10, 14, 19, 21, 22, 23, 24, 25, 27, 28, 29, 32, 36, 37, 38, 39, 40, 41, 47, 53, 54) - Douglas Fry (p 4) - Gérard Uféras (cover, p 3, 6, 9, 26, 41, 52) - Jeanyves Verdu (p 13, 48, 49, 50, 51) - Getty Images (p 13, 44) - Adobe Stock (cover, p 3, 10, 11, 16, 18, 31, 32, 35, 42, 43, 47) - Unsplash (p 10/Enrique Vidal Flores, 11/Nate Holland, 11/Rod Long, 11/Guillaume Perigois, 16/Maria Bobrova, 18/ Mwangi Gatheca, 20/ Oleg Ivanov, 20/ Boris Isaac, 30/Sai de Silva).

Printed in France by Noël Imprimeur Paris - Imprim'Vert® certified printer - on paper from sustainable forests in an ISO 14001 and EMAS certified facility.

Completed March 5, 2025.

Thank you to all patients, healthcare professionals and Stallergenes Greer employees who appear in this publication.

Produced by Stallergenes Greer, Global Communications

Follow us on

www.linkedin.com/company/stallergenesgreer

x.com/StallergenesCom

STALLERGENES GREER INTERNATIONAL AG

Zugerstrasse 76b

6340 Baar, Switzerland

2025_027EN01 May 2025